FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:647-648 March 2, 2000 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Hariharan, S. Related Article by Beniaminovitz, A. PubMed Citation

The concept of drug-induced immunosuppression arose in the late 1950s with the observation by Schwartz and Dameshek that 6-mercaptopurine, developed as an antileukemic drug, was effective in blocking primary, but not secondary, antibody responses in rabbits.¹ Several synthetic congeners prepared by Hitchings and Elion at the Wellcome Laboratories were then screened by Murray and Calne in dogs with renal transplants. With the discovery in 1962 that one of these congeners, azathioprine, was clinically useful as an immunosuppressive drug, the era of clinical organ transplantation began.² The initial success rate for patients receiving cadaveric renal transplants, previously zero, was relatively poor, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Turgeon, N. A., Banuelos, S. J., Shultz, L. D., Lyons, B. L., Iwakoshi, N., Greiner, D. L., Mordes, J. P., Rossini, A. A., Appel, M. C. (2003). Alloimmune Injury and Rejection of Human Skin Grafts on Human Peripheral Blood Lymphocyte-Reconstituted Non-Obese Diabetic Severe Combined Immunodeficient {beta}2-Microglobulin-Null Mice. Exp. Biol. Med. 228: 1096-1104 [Abstract] [Full Text]  
• (2000). Graft Survival After Renal Transplantation. JWatch General 2000: 5-5 [Full Text]